Navigation Links
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Date:9/12/2007

to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media Contact: Investor Contact:

David Schull or Wendy Lau Andreas Marathovouniotis

Russo Partners Russo Partners

212-845-4271 212-845-4253

david.schull@russopartnersllc.com andreas.marathis@russopartnersllc.com

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
3. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
4. Researchers Identify Intracellular Pathway of Alfacells Onconase
5. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
6. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
7. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
10. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
11. NCCN Updates Esophageal and Gastric Cancer Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... NEWS, Va. , Aug. 3, 2015 /PRNewswire/ ... be joining Orthopaedic & Spine Center ... them to manage their chronic pain through psychological ... Robinson is a Fellowship-trained, certified medical psychologist ... pain medicine. His vast experience ranges from assessment ...
(Date:8/3/2015)... , Aug. 3, 2015  BioElectronics Corporation (OTC Pink: ... management, announced that Andrew J. Whelan , President ... his program "On Business" at 9am EDT on Wednesday, ... live, tune to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... the exceptional acceptance the company,s flagship product, ActiPatch Therapy, ...
(Date:8/3/2015)... , Aug. 3, 2015  CytomX, a biopharmaceutical ... cancer, today announced the promotion of several members ... Ray , who previously served as vice president ... promoted to senior vice president of corporate development ... held positions as the vice president of business ...
Breaking Medicine Technology:Orthopaedic & Spine Center Introduces New Pain Psychologist 2UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3
... Radioactive Microspheres in... -- ROME, August 19, 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... Reportlinker.com announces that a new market research ... Advances in Large Scale BioManufacturing and Scale-Up ... A Comprehensive Study of ... This new ASM study provides a clear view ...
Cached Medicine Technology:Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 2Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 3Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 4Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 5Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 6Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 7Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 8Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 9Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED 2Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED 3
(Date:8/4/2015)... ... August 04, 2015 , ... The Law Offices of ... device lawsuit claims dealing with Inferior Vena Cava Filters (“IVC Filters”). , As lead ... cases for Cook IVC Filter clients under In re Cook Medical, Inc., IVC Filters ...
(Date:8/4/2015)... ... August 04, 2015 , ... In ... filed against Johnson & Johnson report that a new location for pretrial proceedings ... regular news updates and cancer warning information at their website, the Talcum Powder ...
(Date:8/4/2015)... ... 04, 2015 , ... Continuing Education Company (CEC) ... interaction simulation session entitled "NOACS: What the Evidence Shows in Managing AFib, ... Inc. and EDUmotion US LLC. , This special activity was recently presented during ...
(Date:8/4/2015)... ... 04, 2015 , ... Lightning Labels is pleased to announce ... will usher in a new standard of sticker and label-making for the company. ... its twin objectives of quality and quantity without compromising the signature lightning-fast speed ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... results have been impressive so far". , Mr Cauchois attributes the success ... French sales partner Dicma and the healthcare technology offered by Winscribe's platform. ...
Breaking Medicine News(10 mins):Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4
... appearance of a cold sore is,a sign that your ... emerge, according to John Sherman, ND, noted naturopathic,physician and ... 80% and 90% of the adult population have the ... Dr. Sherman, who,is the author of The Complete Botanical ...
... Patient safety incidents cost the federal Medicare ... preventable deaths during 2004 through 2006, according to ... Study. HealthGrades, analysis of 41 million Medicare patient ... had, on average, a 43 percent lower chance ...
... WALTHAM, Mass., April 7, 2008 Repligen,Corporation (Nasdaq: ... and,Chief Executive Officer, Walter C. Herlihy, Ph.D., will host ... at 9:00 a.m. EDT, to provide,an update on the ... Thomson/CCBN and can be accessed via,Repligen,s website at ...
... from China is no cause for alarm , , MONDAY, ... probable case of human-to-human transmission of bird flu in ... that there,s a genetic component to human-to-human transmission of ... "This suggests that there,s some genetic component to resistance ...
... ALB ) will hold its quarterly conference call to ... ET., This call is being webcast by Thomson/CCBN and ... in the Investor,Information section., To listen ... In # 800-591-6942 International Dial In ...
... April 7, 2008 American Media, Inc. (AMI),today ... corporate website certain,information currently required to be disclosed ... its amended Senior Secured Credit Agreement., The ... certain key magazine titles during the period April ...
Cached Medicine News:Health News:A Cold Sore Is Often A Warning Sign of Deeper Health Issues, Expert Says 2Health News:Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study 2Health News:Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study 3Health News:Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study 4Health News:Repligen Announces Conference Call to Update Orencia(R) Lawsuit 2Health News:Repligen Announces Conference Call to Update Orencia(R) Lawsuit 3Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 2Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 3Health News:Albemarle Corporation's First Quarter 2008 Earnings Conference Call To Be Held April 22, 2008 at 8:00am ET 2
... This therapeutic system is ... patient in mind. As ... and ongoing therapy, SONOCUR ... and effective therapy. Plus, ...
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... only one of the most modern lithotripters available ... from being designed for the treatment of the ... the MODULITH SLX can also be employed for ... equally suitable for the treatment of gallstones or ...
... The MINILITH SL1 developed by STORZ MEDICAL ... extensive experience in the field of kidney ... the specific requirements to be met by ... as has been outlined above. The MINILITH ...
Medicine Products: